FDA-Cleared Medical Device Distribution Business

$13.6M

SDE

5.2x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a distributor of FDA-cleared medical devices positioned at the intersection of clinical technology and supply chain. The listing markets it as a scalable, high-margin platform, and the one hard number that matters is $13.56M in EBITDA against a $70M asking price, a 5.16x multiple. Revenue, margins, founding year, and location are all undisclosed, which is a real problem for a deal of this size.

What we can infer: a business generating this level of EBITDA in FDA-regulated medical device distribution has clearance, contracts, and a functioning supply chain, all of which carry meaningful barriers to entry. Distribution of clinical devices is a recurring, non-discretionary category because hospitals and clinics buy the equipment and consumables regardless of the macro cycle. The FDA clearance itself is an asset that a new entrant cannot replicate quickly.

The headline is thin on substance and heavy on adjectives like "advanced enterprise intelligence," which usually signals a broker dressing up a solid but ordinary distributor. For a buyer with capital, the opportunity is real but the diligence burden is large: you are underwriting an eight-figure check against a listing that discloses almost nothing beyond a single EBITDA line and a growth-positioning reason for sale.

Why we like it

The EBITDA base is substantial at $13.56M, which puts this in lower-middle-market territory rather than a typical SMB. A 5.16x multiple on genuine, verifiable EBITDA at this scale is reasonable and leaves room for leverage and equity return if the numbers hold up.
Medical device distribution is durable and non-discretionary because hospitals, surgery centers, and clinics keep buying clinical equipment and consumables through downturns. Demand is tied to patient volume and standard of care, not consumer confidence.
FDA clearance and established distribution rights function as a real moat. A competitor cannot simply undercut on price because regulatory clearance, vendor relationships, and hospital contracts take years to assemble, which protects margin and market position.
The seller states the reason as positioning for planned growth rather than distress, which suggests the business is not being dumped. If accurate, this points to a stable operation where an operator with capital and channel expertise can push volume without fixing broken fundamentals.

How to improve it

Force full financial disclosure immediately: revenue, gross margin, customer concentration, and product mix. A distributor throwing off $13.56M EBITDA with undisclosed revenue could be running anywhere from 10% to 40% margins, and that range completely changes the risk and the price you should pay.
Map the supplier and manufacturer relationships and secure exclusivity or long-term terms. Distribution businesses live or die on their upstream contracts, so locking in the FDA-cleared product lines under multi-year agreements protects the earnings you are buying.
Expand the hospital and IDN account base by adding dedicated clinical sales reps to existing device lines. If the current EBITDA comes from a concentrated customer set, widening distribution across new health systems is the fastest lever to grow enterprise value.
Layer in recurring consumables and service contracts alongside device sales. Converting one-time equipment placements into ongoing supply and maintenance revenue raises the quality of earnings and justifies a higher exit multiple.
Rationalize working capital by tightening inventory turns and negotiating better payment terms with manufacturers. Medical device distribution ties up significant cash in inventory, and improving turns directly frees capital and improves cash conversion.
Build out the "enterprise intelligence" the listing hints at into a real data or ordering platform for customers. If there is genuine software or analytics, productizing it creates switching costs and a stickier customer base that supports pricing power.
Pursue tuck-in acquisitions of smaller regional device distributors using this as the platform. At this EBITDA scale you can buy competitors at lower multiples and consolidate purchasing power, expanding both geography and product breadth.

Diligence notes

Verify the $13.56M EBITDA against audited or reviewed financials and reconcile it to actual bank deposits and tax returns. With no revenue disclosed and heavy marketing language in the listing, the single most important task is confirming the earnings are real, normalized, and sustainable.
Analyze customer concentration in depth. Medical device distributors often depend on a handful of large hospital systems or GPO contracts, and losing one anchor account could wipe out a large slice of that EBITDA, so understand the top ten customers and contract terms.
Confirm the FDA clearances, who holds them, and whether they transfer with the sale. If clearances sit with manufacturers rather than the distributor, or if key distribution agreements have change-of-control clauses, the moat you are paying for may not survive the transaction.
Scrutinize supplier agreements for exclusivity, termination rights, and pricing terms. A distributor's value collapses if a manufacturer can pull the line or go direct, so verify how locked-in the upstream relationships are and how long they run.
Investigate the true reason for sale beyond the "positioning for growth" language. That phrasing is vague, so probe whether there is a pending regulatory change, a supplier relationship at risk, or margin compression that motivated the owner to sell at this point.
Assess working capital requirements and how much inventory and receivables are needed to run the business. The purchase agreement must specify a normalized working capital peg, because in distribution the cash tied up in inventory can materially change your real all-in cost.

Source

Originally listed on BizBuySell. View original listing →